The present disclosure provides a compound of Formula (I): ##STR00001##
or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

A compound represented by formula (2) or pharmaceutically acceptable salt thereof:

##STR00001##

wherein R.sup.1 represents a hydrogen atom or the like; R.sup.2 represents a methoxy group or the like; R.sup.3 represents a hydrogen atom or the like; R.sup.4 represents an optionally substituted C.sub.1-6 alkyl group or the like; m represents 0, 1, or 2; n represents 0, 1, 2, or 3; L.sup.1 represents —NH—C(═O)—, —C(═O)—NH—, or the like; L.sup.2 represents a single bond or the like; X represents optionally substituted phenyl or the like; Y represents optionally substituted phenyl or the like; and X and Y are bonded at a carbon atom on each ring.

A compound represented by formula (2) or pharmaceutically acceptable salt thereof:

##STR00001##

wherein R.sup.1 represents a hydrogen atom or the like; R.sup.2 represents a methoxy group or the like; R.sup.3 represents a hydrogen atom or the like; R.sup.4 represents an optionally substituted C.sub.1-6 alkyl group or the like; m represents 0, 1, or 2; n represents 0, 1, 2, or 3; L.sup.1 represents —NH—C(═O)—, —C(═O)—NH—, or the like; L.sup.2 represents a single bond or the like; X represents optionally substituted phenyl or the like; Y represents optionally substituted phenyl or the like; and X and Y are bonded at a carbon atom on each ring.

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

N-benzylbenzamides that act as dual soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor γ (PPARγ) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided.

N-benzylbenzamides that act as dual soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor γ (PPARγ) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided.

Compounds of general formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, A, Z.sup.1, Z.sup.2 and Y are as defined herein are useful for treating respiratory disease and other diseases and conditions modulated by TMEM16A.

Provided herein are deuterated compounds and compositions useful in increasing PPARδ activity. The compounds have a formula ##STR00001##
where L.sup.5 comprises at least one deuterium. Exemplary species include ##STR00002##
The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Provided herein are deuterated compounds and compositions useful in increasing PPARδ activity. The compounds have a formula ##STR00001##
where L.sup.5 comprises at least one deuterium. Exemplary species include ##STR00002##
The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).